IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Amar Lulla, et al.

Serial No.:

Filed: April 28, 2006

10/577,760 For: ORAL FORMULATIONS FOR 5-HT-

RECEPTOR AGONISTS, USES AND METHODS OF TREATMENT EMPLOYING THE SAME

Group Art Unit: 1614

Examiner: Not assigned

Confirmation No.: 6964

CERTIFICATE OF FILING

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Pursuant to 37 C.F.R. §1.8, I hereby certify that this correspondence is being electronically submitted to the

INFORMATION DISCLOSURE STATEMENT

Commissioner:

This Information Disclosure Statement, including completed Forms PTO/SB/08A&B, comprises a list of pertinent art of which Applicants are aware. In accordance with 37 C.F.R. 1.98. no paper copies of the U.S. Patents and patent applications are enclosed. Copies of the foreign patents and non-patent literature listed on Forms PTO/SB/08A&B are enclosed herewith.

The submission of this Information Disclosure Statement and Forms PTO/SB/08A&B is not an admission that the art cited is "prior" with respect to the present invention, nor is it a representation that a search has been conducted or that no better art exists. Applicants reserve the right to swear behind or otherwise disprove any alleged "prior" nature of any art cited should the facts support and that situation warrant such an action. It is submitted that the art cited does not constitute a bar to the patentability of Apolicants' invention under 35 U.S.C. 88 102 or 103.

Applicants believe that no fee is due for the filing of this Information Disclosure Statement.

Nonetheless, in the event that a fee is due, please charge it to Deposit Account No. 50-1515 of

Conley Rose, P.C.

Respectfully submitted,

CONLEY ROSE, P.C.

Rodge B. Carro Reg. No. 39,624

5700 Granite Parkway, Suite 330 Plano, Texas 75024 (972) 731-2288 (972) 731-2289 Facsimile

Date: 12-18-06

ATTORNEY FOR APPLICANTS

PTO/SB/08A (07-06)

Under th	e Poperwork Redu	ction Act of 19	95, no persons are required t	U.S. Patent and Trade	roved for use through 09/35/2005, OMB 0651-03 mark Office; U.S. DEPARTMENT OF COMMER tion unless it contains a valid OMB control numb
Substitute for form 1449/PTO		Complete if Known			
		Application Number	10/577,760		
INIE	INFORMATION DISCLOSURE			Filing Date	April 28, 2006
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Amar Lulia
				Art Unit	1614
			recessary)	Examiner Name	N/A
Sheet	1	-6	3	Attorney Docket Number	PAC/eehc/22013US (4137-00800)

			U. S. PATEN	T DOCUMENTS	
Examiner Indels*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patenies or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Pessages or Relevant
	L	Number-Kind Code ^{2 (Various)}			Figures Appear
	AA	US- 5,807,571	09/15/1998	List	
	AB	US- 6,805,654 B2	10/19/2004	Hale, et al.	
	AC	US- 2003/0180352 A1	09/25/2003	Patel, et al.	
		us-			
		US-	1		1
	\vdash	US-	1		1
	-	US-			
		US-			
		US-			
	_	US-			1
		US-			
		us-	1		-

			IGN PATENT DOC			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cried Document	Pages, Columns, Lines, Where Relevant Passages	Г
		Country Code ² Number ⁴ Wind Code ² (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T,
	BA	EP 0 503 440 A1	09/16/1992	Glaxo Group Limited		
	BB	EP 0 546 593 A1	06/16/1993	Glaxo Group Limted		
	BC	GB2162522	02/05/1986	Glaxo Group Limited		L
	BD	WO9426270	11/24/1994	Lohmann Therapie Syst. Lt		
***	BE	WO 01/37816 A2	05/31/2001	Blochemie Gesellschaft M.B.H.		П
	BF	WO 02/09675 A1	02/07/2002	Pfizer Limited		Г.

Systems W. Purchasters and considered, whether or not closion is a confirmence with IMPEP EXP Dure the through cluster if and in conformence and not considered closed only of the form with med communication to specificate. Applicant requires about designation names (potations.* See Not Code of VIII France Considered and anguestating or explored Profit of Note Code of VIII France Code of VIII International Code of VII

Transistion instituted. The conducting VI CPR 1 97 and 1 58. The information is equal to above the call to child the light place of the conduction of the co

Under the Paperwork Radiution Act of 1995, no persons are required:	U.S. Patent and Trade to respond to a collection of informa		
Substitute for form 1449/PTO	Complete If Known		
GENERAL INTERPLO	Application Number	10/577,760	
INFORMATION DISCLOSURE	Filing Date	April 28, 2006	
	First Named Inventor	Amar Lulia	
STATEMENT BY APPLICANT	Art Unit	1614	
(Use as many aheats as necessary)	Examiner Name	N/A	
Sheet 2 of 3	Attorney Docket Number	PAC/eehc/22013US (4137-00800)	

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	No.1	Document Number	Publication Data MM-DD-YYYY	Nama of Patentes or Applicant of Ched Document	Pages, Columns, Lines, Where Railevent Pessages or Relevant Figures Appear
	_	Number-Kind Code ^{2 (Filtroins)}			- Igoror Appear
	1	US-			
		US-	1 1		
		US-			
		US-			
	_	US-	1		
		US-	1		
		US-			
	$\overline{}$	US-	1		
	-	US-			
		US-			
		US-			
	$\overline{}$	US-			<u> </u>
	_	US-			
		us-			

Examiner Initials*	Cite No.3	Foreign Patent Document	Publication Date	Name of Patentas or Applicant of Cited Document	Pegsa, Columns, Linea, Where Relevant Pessages	Г
		Country Code ² Number ⁴ 16nd Code ³ (Filtrown)	MM-DD-YYYY		Or Relevant Figures Appear	T
	BG	WO 02/083219 A1	10/24/2002	Glaxo Group Limited		
	ВН	WO 2004/009085 A2	01/29/2004	Ranbaxy Laboratories Limi		F
	_					Н
	-				-	۲
	-		-		_	ŀ

Examiner	Date	
Examiner Signature	Considered	1

Considers: Die If inference considers, whether or not indicis is in confirmance with bIPEP BID for the integral cubic in oil in confirmance and not considered, foolists only of this from with sact communication to applicant. *Applicant in single children designation number legislation.** Die Robert Confirmance and not considered in the integral cubic in the incident size of the incident size. The integral cubic in the incident size of the inciden

Transferior in allowled.

The collection of individual to inspection by 27 CFR 1 87 and 158. The information is required to dotation or retain a benefit by the public which is to Tile (and by the collection of information is required to the collection of information in the collection of information is retained to this term of the collection of information of infor

PTO/SB/06B (07-06)

Ur	der the Paperwork Rev	duction A	ct of 1995, no persons a	U.S. Patent U.S. Patent re required to respond to a collection	t and Trademark Office; U.S. DEPARTMENT OF COMMERCI of information unless it contains a valid OMB control number
O. Owell	de for form 1449/PTO				Complete if Known
, outside	10 10 10 10 10 10 10 10 10 10 10 10 10 1			Application Number	10/577,760
			CLOSURE	Filing Date	April 28, 2006
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Amar Lulia
	(Use as many sh			Art Unit	1614
	(Ose as many sn	eets 45 /i	ecessary)	Examiner Name	N/A
Shoot	2	-4	2	Attorney Docket Number	DAC(oaba)22012LIC (4127 00900)

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pago(s), volume-issue number(s), publisher, oty aratior country where published.	T ²
	CA	International Search Report and Written Opinion, PCT/GB2004/004805, November 3, 2005, 16 pgs.	
	СВ	Transmittal and Internetional Preliminary Report on Patentability, PCT/GB2004/004805, June 1, 2006, 22 pgs.	

				١
Examiner		Date		
Signature		Considered		
*EXAMINER: II	that if reference considered, whether or not citation is in conformance with MPEP &	9 Drawline through o	station if not in conformance and not	•

"EXAMPLE", their of reterence considered, whether or not continue and example (Fig. C) have be though intention of non-terminal and ordinary of their continues and continues and continues and continues and continues are continued as a continue of their continues are continued as a continue to the continues and continues and continues and continues are continued as a continue to the continues and continues and continues and continues are continued as a continue to the continues and continues and continues are continued as a continue to the continues and continues are continued as a continue to the continue to the continue to the continue to the